Journal of Clinical Pharmacy & Therapeutics

How much is the life of a cancer patient worth? A pharmaco-economic perspective
pp. 249-256(8)
Authors: Simoens, S.; Dooms, M.

A proposed mechanism for chemotherapy-related cognitive impairment (`chemo-fog')
pp. 257-259(3)
Author: Raffa, R. B.

Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes
pp. 260-274(15)
Authors: Ryan, Gina J.; Hardy, Yolanda

Treatment of irritable bowel syndrome
pp. 275-282(8)
Authors: Trinkley, K. E.; Nahata, M. C.

Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example
pp. 283-298(16)
Authors: Raffa, R. B.; Pergolizzi Jr, J. V.

A review of tumour lysis syndrome with targeted therapies and the role of rasburicase
pp. 299-326(28)
Authors: Bose, P.; Qubaiah, O.

Hepatotoxicity of therapeutic short-course paracetamol in hospital inpatients: impact of ageing and frailty
pp. 327-335(9)
Authors: Mitchell, S. J.; Hilmer, S. N.; Murnion, B. P.; Matthews, S.

Managing statin-induced muscle toxicity in a lipid clinic
pp. 336-341(6)
Authors: Blaier, O.; Lishner, M.; Elis, A.

Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline
pp. 342-347(6)
Authors: Yeh, Y.; Slovik, D.; Carter, D.; Clapp, M.; Churchill, W.; Reddy, P.

Perceived feasibility of a community pharmacy-based asthma intervention: a qualitative follow-up study
pp. 348-355(8)
Authors: Bereznicki, B.; Peterson, G.; Jackson, S.; Haydn Walters, E.; DeBoos, I.; Hintz, P.

Doctors' beliefs and knowledge on corticosteroid-induced osteoporosis: identifying barriers to improve prevention
pp. 356-366(11)
Authors: Duyvendak, M.; Naunton, M.; van Roon, E. N.; Brouwers, J. R. B. J

Lay perspectives on the use of biologically based therapies in the context of cancer: a qualitative study from Sweden
pp. 367-375(9)
Authors: Hök, J.; Falkenberg, T.; Tishelman, C.

Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements
pp. 376-382(7)
Authors: van Berlo-van de Laar, I. R. F.; Vermeij, C. G.; Doorenbos, C. J.

Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration
pp. 383-389(7)
Authors: Ren, X. S.; Crivera, C.; Sikirica, M.; Dirani, R.; Qian, S.; Kazis, L. E.

Modelling the atypical absorption of menatetrenone and the metabolism to its epoxide: effect of VKORC1 polymorphism
pp. 390-398(9)
Authors: Baek, I. H.; Kang, W.; Yun, H. Y.; Lee, S. S.; Kwon, K. I.

Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy
pp. 399-405(7)
Authors: Kim, S. H.; Ye, Y. M.; Lee, H. Y.; Sin, H. J.; Park, H. S.

Pharmacokinetics of midazolam tablet in different Chinese ethnic groups
pp. 406-411(6)
Authors: Guo, T.; Mao, G.-F.; Xia, D.-Y.; Su, X.-Y.; Zhao, L.-S.

New treatment of free-radical scavenger in adrenoleukodystrophy
pp. 412-415(4)
Authors: Kawashima, H.; Nishimata, S.; Ishii, C.; Yamanaka, G.; Kashiwagi, Y.; Takekuma, K.; Hoshika, A.; Watanabe, Y.

Chronic cough associated with interferon/ribavirin therapy for hepatitis C
pp. 416-418(3)
Authors: Dicpinigaitis, P. V.; Weiner, F. R.

Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition
pp. 419-425(7)
Authors: Hu, M.; Mak, V. W. L.; Tomlinson, B.

Possible long-acting risperidone-induced hypothermia precipitating phenytoin toxicity in an elderly patient
pp. 426-429(4)
Authors: Brandon Bookstaver, P.; Miller, A. D.

Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine
pp. 430-432(3)
Authors: De Dios, C.; Fudio, S.; Lorenzo, A.

The treatment of pulmonary Wangiella dermatitidis infection with oral voriconazole
pp. 433-436(4)
Author: Bulloch, M. N.